GSK plc
An institutional investment manager in London. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 13, 2026. SEC CIK 1131399.
- Reported value$602.2m
- Positions13
Holdings: 13 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Crispr Therapeutics AG | NAMEN AKT | H17182108 | 176 | 29.2% | 3,220,627 | Unchanged | |
| Wave Life Sciences Ltd | SHS | Y95308105 | 106 | 17.6% | 18,245,691 | Unchanged | |
| VIR Biotechnology IncVIR | COM | 92764N102 | 87.1 | 14.5% | 8,550,954 | Unchanged | |
| Biontech SEBNTX | SPONSORED ADS | 09075V102 | 82.8 | 13.7% | 889,824 | Unchanged | |
| Ideaya Biosciences IncIDYA | COM | 45166A102 | 49.7 | 8.3% | 1,333,333 | Unchanged | |
| Cytokinetics IncCYTK | COM NEW | 23282W605 | 29.0 | 4.8% | 340,434 | Unchanged | |
| Lyell Immunopharma IncLYEL | COM NEW | 55083R203 | 21.3 | 3.5% | 1,512,659 | Unchanged | |
| Spero Therapeutics IncSPRO | COM | 84833T103 | 20.3 | 3.4% | 9,190,606 | Unchanged | |
| Nkarta IncNKTX | COM | 65487U108 | 8.9 | 1.5% | 3,150,732 | Unchanged | |
| Fulcrum Therapeutics IncFULC | COM | 359616109 | 6.5 | 1.1% | 1,785,714 | Unchanged | |
| Bicycle Therapeutics plcBCYC | SPONSORED ADS | 088786108 | 6.5 | 1.1% | 1,529,561 | Unchanged | |
| CVRX IncCVRX | COM | 126638105 | 5.2 | 0.9% | 1,007,583 | Unchanged | |
| Regenxbio IncRGNX | COM | 75901B107 | 3.3 | 0.5% | 271,456 | Unchanged |
Source: SEC EDGAR, Form 13F-HR, accession 0001999371-26-017873 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.